3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
15
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Small Cell Lung Carcinoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Acute
2
Carcinoma, Non-Small-Cell Lung
2
Recurrence
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Hodgkin Disease
1
Carcinoma, Small Cell
1
Interventions
Rituximab
130
Cyclophosphamide
41
Bendamustine Hydrochloride
39
venetoclax
25
fludarabine
25
obinutuzumab
24
Lenalidomide
23
ibrutinib
22
Gemcitabine
22
Vincristine
20
Prednisone
20
tositumomab I-131
19
Doxorubicin
19
plerixafor
14
Dexamethasone
14
Granulocyte Colony-Stimulating Factor
12
pirtobrutinib
11
Brentuximab Vedotin
11
glofitamab
10
tocilizumab
9
pembrolizumab
9
ibritumomab tiuxetan
9
Etoposide
9
Azacitidine
9
polatuzumab vedotin
8
parsaclisib
8
copanlisib
8
acalabrutinib
8
Drug Therapy
8
ublituximab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Non-Hodgkin
×
etoposide phosphate
×
Clear all
NCT06230224
2026-05-11
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3
Active not recruiting
216 enrolled